Secukinumab for non-radiographic axial spondyloarthritis
DOI: 10.32364/2587-6821-2021-5-5-294-300
I.Z. Gaydukova1,2, V.I. Mazurov1,2, O.V. Inamova1,2
1North-Western State Medical University named after I.I. Mechnikov, Saint-Petersburg,
Russian Federation
2Clinical Rheumatological Hospital No. 25, Saint-Petersburg, Russian Federation
Since 2009, the concepts of axial spondyloarthritis (axSpA) and peripheral spondyloarthritis (pSpA) have been used, while the radiographic phenotype (r-axSpA) and the non-radiographic phenotype (nr-axSpA) are distinguished. Nowadays, the treatment of nr-axSpA is carried out in the same way as r-axSpA. At the same time, it is obvious that nr-axSpA is more heterogeneous than radiographic, which can determine the peculiarities of patient management tactics. The authors cited 2 clinical cases in which they demonstrated the possibility of achieving persistent drug-free remission at an early (less than 6 months from the first occurrence of disease signs) use of secukinumab in patients with nr-axSpA. The clinical, laboratory and radiological data of two patients meeting the criteria of the SpondyloArthritis International Society are presented in detail. The clinical cases described in this paper are of considerable interest to practitioners since they present the fir st experience of using this drug in patients with nr-axSpA outside the clinical studies. Also, they can become a part of the clinical experience that will form the basis for further nr-axSpA study with the subsequent development of individual clinical recommendations for the treatment of this disease.
Keywords: axial spondyloarthritis, non-radiographic axial spondyloarthritis, secukinumab, early treatment, remission.
For citation: Gaydukova I.Z., Mazurov V.I., Inamova O.V. Secukinumab for non-radiographic axial spondyloarthritis. Russian Medical Inquiry. 2021;5(5):294–300 (in Russ.). DOI: 10.32364/2587-6821-2021-5-5-294-300.
Aknowledgement
The technical edition is supported by Novartis.
About the authors:
Inna Z. Gaydukova — Dr. Sc. (Med.), Head of the Research Institute of Rheumatology, Professor of the Department of Therapy, Rheumatology, Temporary Disability Examination and Quality of Medical Care named after E.E. Eichwald, North-Western State Medical University named after I.I. Mechnikov; 41, Kirochnaya str., Saint Petersburg, 191015, Russian Federation; Clinical Rheumatological Hospital No. 25; 30, Bolshaya Podyacheskayа str., Saint Petersburg, 190068, Russian Federation; ORCID iD 0000-0003-3500-7256.
Vadim I. Mazurov — Academician of the Russian Academy of Sciences, Honored Scientist of the Russian Federation, Dr. Sc. (Med.), Professor, Chief Scientific Consultant, Director of the Research Institute of Rheumatology, Head of the Department of Therapy, Rheumatology, Temporary Disability Examination and Quality of Medical Care named after E.E. Eichwald, North-Western State Medical University named after I.I. Mechnikov; 41, Kirochnaya str., Saint Petersburg, 191015, Russian Federation; Head of the Center of Autoimmune Diseases, Clinical Rheumatological Hospital No. 25; 30, Bolshaya Podyacheskayа str., Saint Petersburg, 190068, Russian Federation; ORCID iD 0000-0002-0797-2051.
Oksana V. Inamova — C. Sc. (Med.), Chief Officer of Clinical Rheumatological Hospital No. 25; 30, Bolshaya Podyacheskayа str., Saint Petersburg, 190068, Russian Federation; Head of the Research Institute of Rheumatology, Assistant Professor of the Department of Therapy, Rheumatology, Temporary Disability Examination and Quality of Medical Care named after E.E. Eichwald, North-Western State Medical University named after I.I. Mechnikov; 41, Kirochnaya str., Saint Petersburg, 191015, Russian Federation; ORCID iD 0000-0001-9126-3639.
Contact information: Inna Z. Gaydukova, e-mail: ubp1976@list.ru.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 13.07.2021.
Revised 05.08.2021.
Accepted 30.08.2021.
2. Erdes Sh.F., Badokin V.V., Bochkova A.G. et al. About the terminology of spondyloarthritis. Nauchno-prakticheskaya revmatologiya. 2015;53(6):657–660 (in Russ.). DOI: 10.14412/1995-4484-2015-657-660.
3. Erdes Sh.F., Rebrov A.P., Dubinina T.V. et al. Spondyloarthritis: modern terminology and definitions. Terapevticheskiy arkhiv. 2019;91(5):84–88 (in Russ.). DOI: 10.26442/00403660.2019.05.000208.
4. Hebeisen M., Micheroli R., Scherer A. et al. Spinal radiographic progression in axial spondyloarthritis and the impact of classification as nonradiographic versus radiographic disease: Data from the Swiss Clinical Quality Management cohort. PLoS One. 2020;15(3):e0230268. DOI: 10.1371/journal.pone.0230268.
5. Deodhar A., Blanco R., Dokoupilová E. et al. Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo-Controlled Phase III Study. Arthritis Rheumatol. 2021;73(1):110–120. DOI: 10.1002/art.41477.
6. Dubinina T.V., Gaidukova I.Z., Godzenko A.A. et al. Recommendations for assessing the activity of the disease and the functional state of patients with ankylosing spondylitis in clinical practice. Nauchno-prakticheskaya revmatologiya. 2017;55(4):344–350 (in Russ.). DOI: 10.14412/1995-4484-2017-344-350.
7. Gaidukova I.Z., Rebrov A.P., Korotaeva T.V. et al. Remission in axial spondyloarthritis — definition and assessment tools (recommendations of the Expert group for the study of spondyloarthritis at the All-Russian public organization "Association of rheumatologists of Russia"). Nauchno-prakticheskaya revmatologiya. 2018;56(1):10–14 (in Russ.). DOI: 10.14412/1995-4484-2018-10-14.
8. Gaidukova I.Z., Rebrov A.P., Lapshina S.A. et al. The use of non-steroidal anti-inflammatory drugs and genetically engineered biological drugs for the treatment of axial spondyloarthritis. Recommendations of the Expert Group for the Study of Spondyloarthritis at the All-Russian Public Organization "Association of Rheumatologists of Russia". Nauchno-prakticheskaya revmatologiya. 2017;55(5):474–484 (in Russ.). DOI: 10.14412/1995-4484-2017-474-484.
9. Braun J., Baraliakos X., Deodhar A. et al. Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study. Rheumatology (Oxford). 2019;58(5):859–868. DOI: 10.1093/rheumatology/key375.
10. Protopopov M., Poddubnyy D. Radiographic progression in non-radiographic axial spondyloarthritis. Expert Rev Clin Immunol. 2018;14(6):525–533. DOI: 10.1080/1744666X.2018.1477591.
11. Deodhar A., Strand V., Kay J., Braun J. The term ‘non-radiographic axial spondyloarthritis’ is much more important to classify than to diagnose patients with axial spondyloarthritis. Ann Rheum Dis. 2016;75(5):791–794. DOI: 10.1136/annrheumdis-2015-208852.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Распечатать